M. Lange

2.9k total citations · 1 hit paper
7 papers, 2.2k citations indexed

About

M. Lange is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, M. Lange has authored 7 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Rheumatology, 3 papers in Immunology and 2 papers in Hematology. Recurrent topics in M. Lange's work include Rheumatoid Arthritis Research and Therapies (3 papers), Biosimilars and Bioanalytical Methods (2 papers) and Statistical Methods in Clinical Trials (2 papers). M. Lange is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (3 papers), Biosimilars and Bioanalytical Methods (2 papers) and Statistical Methods in Clinical Trials (2 papers). M. Lange collaborates with scholars based in United States, Austria and Canada. M. Lange's co-authors include Daniel Burge, Michael E. Weinblatt, Ken J. Bulpitt, Joel M. Kremer, Roy Fleischmann, Arthur D. Bankhurst, Robert I. Fox, Jennifer J. Anderson, David T. Felson and George A. Wells and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Arthritis & Rheumatism.

In The Last Decade

M. Lange

7 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate

1999 1.6k citations Michael E. Weinblatt, Joel M. Kremer et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Lange United States	6	1.7k	941	574	277	261	7	2.2k
Ken J. Bulpitt United States	21	1.9k 1.2×	888 0.9×	778 1.4×	326 1.2×	381 1.5×	33	2.9k
Scott W. Baumgartner United States	16	1.4k 0.8×	1.0k 1.1×	766 1.3×	232 0.8×	264 1.0×	18	2.5k
William Shergy United States	19	1.2k 0.7×	481 0.5×	561 1.0×	300 1.1×	274 1.0×	24	1.9k
John Han United States	17	1.9k 1.1×	831 0.9×	754 1.3×	261 0.9×	205 0.8×	20	2.3k
Y P M Goekoop-Ruiterman Netherlands	20	2.4k 1.4×	880 0.9×	399 0.7×	485 1.8×	225 0.9×	30	2.6k
Jonathan S. Coblyn United States	21	1.2k 0.7×	466 0.5×	443 0.8×	368 1.3×	265 1.0×	34	2.1k
J-C Becker United States	13	1.7k 1.0×	745 0.8×	484 0.8×	431 1.6×	290 1.1×	17	2.1k
Joseph Wajdula United States	21	2.7k 1.6×	1.2k 1.3×	1.1k 2.0×	479 1.7×	254 1.0×	35	3.4k
S. Kary Germany	19	1.6k 1.0×	668 0.7×	876 1.5×	223 0.8×	166 0.6×	23	2.2k
J.H.L.M. van Groenendael Netherlands	16	1.9k 1.1×	744 0.8×	324 0.6×	406 1.5×	175 0.7×	22	2.1k

Countries citing papers authored by M. Lange

Since Specialization

Citations

This map shows the geographic impact of M. Lange's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Lange with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Lange more than expected).

Fields of papers citing papers by M. Lange

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Lange. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Lange. The network helps show where M. Lange may publish in the future.

Co-authorship network of co-authors of M. Lange

This figure shows the co-authorship network connecting the top 25 collaborators of M. Lange. A scholar is included among the top collaborators of M. Lange based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Lange. M. Lange is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Lovell, Daniel J., Edward H. Giannini, Andreas Reiff, et al.. (2003). Long‐term efficacy and safety of etanercept in children with polyarticular‐course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open‐label, extended‐treatment trial. Arthritis & Rheumatism. 48(1). 218–226. 182 indexed citations

2.

Gestel, Anke M. van, Jennifer J. Anderson, Piet L. C. M. van Riel, et al.. (1999). ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology.. PubMed. 26(3). 705–11. 213 indexed citations

3.

Weinblatt, Michael E., Joel M. Kremer, Arthur D. Bankhurst, et al.. (1999). A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate. New England Journal of Medicine. 340(4). 253–259. 1612 indexed citations breakdown →

4.

Jones, Stephen E., Pankaj Khandelwal, Kristi McIntyre, et al.. (1999). Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Hematopoietic Growth Factor PIXY321 After Moderate-Dose Fluorouracil, Doxorubicin, and Cyclophosphamide in Stage II and III Breast Cancer. Journal of Clinical Oncology. 17(10). 3025–3032. 6 indexed citations

5.

Felson, David T., Jennifer J. Anderson, M. Lange, George A. Wells, & Michael P. LaValley. (1998). Should imporvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?. Arthritis & Rheumatism. 41(9). 1564–1570. 160 indexed citations

6.

Felson, David T., Jennifer J. Anderson, M. Lange, George A. Wells, & Michael P. LaValley. (1998). Should imporvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?. Arthritis & Rheumatism. 41(9). 1564–1570. 42 indexed citations

7.

Lange, M., et al.. (1993). Ist die innere Peritonealisierung nach Sectio caesarea erforderlich?. Gyn�kologisch-geburtshilfliche Rundschau. 33(1). 264–264. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact